1.Xipell M, Lledó GM, Egan AC, Tamirou F, del Castillo CS, Rovira J, et al. From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Autoimmunity Reviews. 2023;22(10):103404.
2.Jayne D, Rovin B, Mysler E, Furie R, Houssiau F, Trasieva T, et al. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus science & medicine. 2023;10(2).
3.Visvanathan S, Daniluk S, Ptaszyński R, Müller-Ladner U, Ramanujam M, Rosenstock B, et al. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Annals of the rheumatic diseases. 2019;78:754-60.
4.Chan SCW, Wang YF, Yap DYH, Chan TM, Lau YL, Lee PPW, et al. Risk and Factors associated with disease manifestations in systemic lupus erythematosus - lupus nephritis (RIFLE-LN): a ten-year risk prediction strategy derived from a cohort of 1652 patients. Frontiers in immunology. 2023;14:1200732.
5.Banos A, Bertsias G. Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention. Current rheumatology reports. 2023;25(10):183-91.
6.Jia Q, Ma F, Zhao J, Yang X, Sun R, Li R, et al. Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: A retrospective cohort study. Frontiers in pharmacology. 2022;13:946165.
7.Hunnicutt JN, Georgiou ME, Ma L, Levy RA, Gairy K. Real-World Immunosuppressant Treatment Patterns for Patients with Lupus Nephritis in the United States. Rheumatology and therapy. 2023;10(5):1305-18.
8.Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatology and therapy. 2020;7(3):433-46.
9.Muñoz-Grajales C, Yilmaz EB, Svenungsson E, Touma Z. Systemic lupus erythematosus and damage: What has changed over the past 20 years? Best Practice & Research Clinical Rheumatology. 2023;37(4):101893.
10.Tavares LCP, Caetano LdVN, Ianhez M. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. Anais Brasileiros de Dermatologia. 2024;99(2):259-68.
11.Rojas-Rivera JE, García-Carro C, Ávila AI, Espino M, Espinosa M, Fernández-Juárez G, et al. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Clinical kidney journal. 2023;16(9):1384-402.
12.Arora S, Rovin BH. Expert Perspective: An Approach to Refractory Lupus Nephritis. Arthritis & Rheumatology. 2022;74(6):915-26.
13.Strohm L, Ubbens H, Münzel T, Daiber A, Daub S. Role of CD40(L)-TRAF signaling in inflammation and resolution-a double-edged sword. Frontiers in pharmacology. 2022;13:995061.
14.Bullock TNJ. CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cellular & Molecular Immunology. 2022;19(1):14-22.
15.Tian S, Wang Y, Wan J, Yang M, Fu Z. Co-stimulators CD40-CD40L, a potential immune-therapy target for atherosclerosis: A review. Medicine. 2024;103(14):e37718.
16.Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduction and Targeted Therapy. 2024;9(1):68.
17.Hinkley H, Counts DA, VonCanon E, Lacy M. T Cells in Atherosclerosis: Key Players in the Pathogenesis of Vascular Disease. Cells. 2023;12(17).
18.Bosmans LA, Bosch L, Kusters PJH, Lutgens E, Seijkens TTP. The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease. Journal of cardiovascular translational research. 2021;14(1):13-22.
19.Ramanujam M, Steffgen J, Visvanathan S, Mohan C, Fine JS, Putterman C. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev. 2020;19(11):102668.
20.Daei Sorkhabi A, Komijani E, Sarkesh A, Ghaderi Shadbad P, Aghebati-Maleki A, Aghebati-Maleki L. Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice. Cell Communication and Signaling. 2023;21(1):321.
21.Díaz Á, González-Alayón I, Pérez-Torrado V, Suárez-Martins M. CD40-CD154: A perspective from type 2 immunity. Seminars in Immunology. 2021;53:101528.
22.Laidlaw BJ, Cyster JG. Transcriptional regulation of memory B cell differentiation. Nature Reviews Immunology. 2021;21(4):209-20.
23.He Y, Vinuesa CG. Chapter Four - Germinal center versus extrafollicular responses in systemic autoimmunity: Who turns the blade on self? In: Alt FW, Murphy KM, editors. Advances in Immunology. 162: Academic Press; 2024. p. 109-33.
24.Schaier M, Gottschalk C, Uhlmann L, Speer C, Kälble F, Eckstein V, et al. Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients. Arthritis Research & Therapy. 2018;20(1):278.
25.Hernandez M, Shen L, Rock K. CD40-CD40 Ligand Interaction between Dendritic Cells and CD8+ T Cells Is Needed to Stimulate Maximal T Cell Responses in the Absence of CD4+ T Cell Help. Journal of immunology (Baltimore, Md : 1950). 2007;178:2844-52.
26.Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Advanced drug delivery reviews. 2019;141:92-103.
27.Troise D, Infante B, Mercuri S, Catalano V, Ranieri E, Stallone G. Dendritic Cells: A Bridge between Tolerance Induction and Cancer Development in Transplantation Setting. Biomedicines [Internet]. 2024; 12(6).
28.Mosser DM, Hamidzadeh K, Goncalves R. Macrophages and the maintenance of homeostasis. Cellular & Molecular Immunology. 2021;18(3):579-87.
29.Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy. 2021;6(1):263.
30.Balogh L, Oláh K, Sánta S, Majerhoffer N, Németh T. Novel and potential future therapeutic options in systemic autoimmune diseases. Frontiers in immunology. 2024;15.
31.Canny SP, Jackson SW. B Cells in Systemic Lupus Erythematosus: From Disease Mechanisms to Targeted Therapies. Rheumatic diseases clinics of North America. 2021;47(3):395-413.
32.Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Human vaccines & immunotherapeutics. 2018;14(12):2820-41.
33.Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, et al. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. Arthritis & rheumatology (Hoboken, NJ). 2021;73(5):826-36.
34.Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. 2023;82(5):639-45.
35.Pucino V, Gardner DH, Fisher BA. Rationale for CD40 pathway blockade in autoimmune rheumatic disorders. The Lancet Rheumatology. 2020;2(5):e292-e301.
36.da Rosa LC, Scales HE, Benson RA, Brewer JM, McInnes IB, Garside P. The effect of abatacept on T-cell activation is not long-lived in vivo. Discovery immunology. 2024;3(1):kyad029.
37.Wofsy D, Hillson J, Diamond B. Abatacept for lupus nephritis Alternative definitions of complete response support conflicting conclusions. Arthritis and rheumatism. 2012;64.
38.Pinelli DF, Ford ML. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. Immunotherapy. 2015;7(4):399-410.
39.Ots HD, Tracz JA, Vinokuroff KE, Musto AE. CD40-CD40L in Neurological Disease. International journal of molecular sciences. 2022;23(8).
40.Madaudo C, Coppola G, Parlati AL, Corrado E. Discovering Inflammation in Atherosclerosis: Insights from Pathogenic Pathways to Clinical Practice. International journal of molecular sciences [Internet]. 2024; 25(11).
41.Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al. Pathophysiology of Atherosclerosis. International journal of molecular sciences. 2022;23(6).
42.Bosmans LA, van Tiel CM, Aarts S, Willemsen L, Baardman J, van Os BW, et al. Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages’ transition into a pro-inflammatory state. Cardiovascular research. 2023;119(5):1146-60.
43.Yung S, Yap DY, Chan TM. Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. F1000Research. 2017;6:874.
44.Allard CC, Salti S, Mourad W, Hassan GS. Implications of CD154 and Its Receptors in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Cells [Internet]. 2024; 13(19).
45.Zhang S, Breidenbach JD, Russell BH, George J, Haller ST. CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease. Journal of clinical medicine. 2020;9(11).
46.Cognasse F, Duchez AC, Audoux E, Ebermeyer T, Arthaud CA, Prier A, et al. Platelets as Key Factors in Inflammation: Focus on CD40L/CD40. Frontiers in immunology. 2022;13:825892.
47.Daub S, Lutgens E, Münzel T, Daiber A. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease—The Pros and Cons for Cardioprotection. International journal of molecular sciences [Internet]. 2020; 21(22).
48.Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends in molecular medicine. 2017;23(7):615-35.
49.Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World journal of pediatrics : WJP. 2020;16(1):19-30.
50.Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Current opinion in rheumatology. 2021;33(2):197-204.
51.Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacology & therapeutics. 2021;219:107709.
52.Roveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, et al. Lupus Nephritis from Pathogenesis to New Therapies: An Update. International journal of molecular sciences [Internet]. 2024; 25(16).
53.St. Clair EW, Baer AN, Ng W-F, Noaiseh G, Baldini C, Tarrant TK, et al. CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nature Medicine. 2024;30(6):1583-92.
54.Allard CC, Salti S, Mourad W, Hassan GS. Implications of CD154 and Its Receptors in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Cells. 2024;13(19).
55.Perper SJ, Westmoreland SV, Karman J, Twomey R, Seagal J, Wang R, et al. Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus. J Immunol. 2019;203(1):58-75.
56.Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford, England). 2021;60(11):5397-407.
57.Chamberlain C, Colman P, Ranger A, Burkly L, Johnston G, Otoul C, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Annals of the Rheumatic Diseases. 2017;76:annrheumdis-2017.
58.Schwabe C, Rosenstock B, Doan T, Hamilton P, Dunbar PR, Eleftheraki AG, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases. Journal of clinical pharmacology. 2018;58(12):1566-77.
59.Mansour I, Murugapandian S, Tanriover B, Thajudeen B. Contemporary Monoclonal Antibody Utilization in Glomerular Diseases. Mayo Clinic proceedings Innovations, quality & outcomes. 2023;7(4):276-90.
60.Lee WS, Amengual O. B cells targeting therapy in the management of systemic lupus erythematosus. Immunological Medicine. 2020;43(1):16-35.
61.Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, et al. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Science translational medicine. 2019;11(489).
62.Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmunity Reviews. 2019;18(3):306-11.
63.Ramanujam M, Steffgen J, Visvanathan S, Mohan C, Fine J, Putterman C. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmunity reviews. 2020;19:102668.
64.Espié P, He Y, Koo P, Sickert D, Dupuy C, Chokoté E, et al. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody. American Journal of Transplantation. 2020;20(2):463-73.
65.Ahsan NF, Lourenço S, Psyllou D, Long A, Shankar S, Bashford-Rogers R. The current understanding of the phenotypic and functional properties of human regulatory B cells (Bregs). Oxford Open Immunology. 2024;5(1):iqae012.
66.Neves A, Viveiros L, Venturelli V, Isenberg DA. Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities. Research and reports in urology. 2023;15:333-53.
67.Shock A, Burkly L, Wakefield I, Peters C, Garber E, Ferrant J, et al. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015;17(1):234.
68.Reis-Neto ETd, Seguro LPC, Sato EI, Borba EF, Klumb EM, Costallat LTL, et al. II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment. Advances in Rheumatology. 2024;64(1):48.
69.Ji L, Li T, Chen H, Yang Y, Lu E, Liu J, et al. The crucial regulatory role of type I interferon in inflammatory diseases. Cell & bioscience. 2023;13(1):230.
70.Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. 2023;82(8):999-1014.
71.Luo R, Chang D, Zhang N, Cheng Y, Ge S, Xu G. T Follicular Helper Cells in Tertiary Lymphoid Structure Contribute to Renal Fibrosis by IL-21. International journal of molecular sciences. 2023;24(16).
72.Tecklenborg J, Clayton D, Siebert S, Coley SM. The role of the immune system in kidney disease. Clinical and experimental immunology. 2018;192(2):142-50.
73.Leibler C, Thiolat A, Elsner RA, El Karoui K, Samson C, Grimbert P. Costimulatory blockade molecules and B-cell–mediated immune response: current knowledge and perspectives. Kidney International. 2019;95(4):774-86.
74.Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. Journal of biomedicine & biotechnology. 2011;2011:271694.
75.Boumpas D, Furie R, Manzi S, Illei G, Wallace D, Balow J, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis and rheumatism. 2003;48:719-27.
76.Law C-L, Grewal I. Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges. Advances in experimental medicine and biology. 2009;647:8-36.
77.Nie H, Chang S, Li Y, Li F. Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis. Biomolecules [Internet]. 2023; 13(11).
78.Shock A, Burkly L, Wakefield I, Peters C, Garber E, Ferrant J, et al. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: An in vivo study. Arthritis research & therapy. 2015;17:234.
79.Jayne DR, Steffgen J, Romero-Diaz J, Bajema I, Boumpas DT, Noppakun K, et al. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Arthritis & rheumatology (Hoboken, NJ). 2023;75(11):1983-93.
80.Visvanathan S, Daniluk S, Ptaszyński R, Müller-Ladner U, Ramanujam M, Rosenstock B, et al. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Ann Rheum Dis. 2019;78(6):754-60.
81.Flandre TD, Mansfield KG, Espié PJ, Rubic-Schneider T, Ulrich P. Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study. 2022;50(5):712-24.
82.Kaneko M, Jackson SW. Recent advances in immunotherapies for lupus nephritis. Pediatric nephrology (Berlin, Germany). 2023;38(4):1001-12.
83.St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, et al. CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024;30(6):1583-92.
84.Nicholson SM, Casey KA, Gunsior M, Drabic S, Iverson W, Cook H, et al. The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. British journal of pharmacology. 2020;177(5):1061-76.
85.Fisher BA, Szanto A, Ng WF, Bombardieri M, Posch MG, Papas AS, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. The Lancet Rheumatology. 2020;2(3):e142-e52.
86.Singh AK, Goerlich CE, Zhang T, Lewis BGT, Hershfeld A, Mohiuddin MM. CD40-CD40L Blockade: Update on Novel Investigational Therapeutics for Transplantation. Transplantation. 2023;107(7):1472-81.
87.Kawai T, Andrews D, Colvin R, Sachs D, Cosimi A. Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature medicine. 2000;6:114.
88.Tsuda Y, Grimaldi C, Huang F, Benediktus E, Yagi N, Padula SJ, et al. Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects. British journal of clinical pharmacology. 2021;87(4):2000-13.
89.Jayne D, Steffgen J, Romero-Diaz J, Amano H, Noppakun K, Gomez HM, et al. POS0687 A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS. 2021;80(Suppl 1):589-90.
90.Espié P, He Y, Koo P, Sickert D, Dupuy C, Chokoté E, et al. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020;20(2):463-73.
91.Tocoian A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley R, et al. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 2015;24(10):1045-56.
92.Tang B, Yang X. Clinical advances in immunotherapy for immune-mediated glomerular diseases. Clinical and experimental medicine. 2023;23(8):4091-105.